Page 131 - 《中国药房》2024年20期

识：2022 版[J]. 中华临床感染病杂志，2022，15（5）： [15] KOFLA G，RUHNKE M. Pharmacology and metabolism
321-332. of anidulafungin，caspofungin and micafungin in the treat‐
Working Group of Expert Consensus on Clinical Use of ment of invasive candidosis：review of the literature[J].
Posaconazole. Expert consensus on clinical use of Eur J Med Res，2011，16（4）：159-166.
posaconazole：2022 edition[J]. Chin J Clin Infect Dis， [16] ABDUL-AZIZ M H，ALFFENAAR J C，BASSETTI M，
2022，15（5）：321-332. et al. Antimicrobial therapeutic drug monitoring in criti‐
[ 7 ] JOHN J，LOO A，MAZUR S，et al. Therapeutic drug cally ill adult patients：a position paper[J]. Intensive Care
monitoring of systemic antifungal agents：a pragmatic Med，2020，46（6）：1127-1153.
approach for adult and pediatric patients[J]. Expert Opin [17] STOTT K. The pharmacokinetics and pharmacodynamics
Drug Metab Toxicol，2019，15（11）：881-895. of antifungal agents for HIV-associated invasive fungal
[ 8 ] ANDES D，KOVANDA L，DESAI A，et al. Isavuconazole infections[D].Liverpool：University of Liverpool，2021.
concentration in real-world practice：consistency with [18] RIGHI E，CARNELUTTI A，BACCARANI U，et al.
results from clinical trials[J]. Antimicrob Agents Che‐ Treatment of Candida infections with fluconazole in adult
mother，2018，62（7）：e00585-e00518. liver transplant recipients：is TDM-guided dosing adapta‐
[ 9 ] COJUTTI P G，CARNELUTTI A，LAZZAROTTO D，et tion helpful?[J] Transpl Infect Dis，2019，21（4）：e13113.
al. Population pharmacokinetics and pharmacodynamic [19] BOONSTRA J M，MÄRTSON A G，SANDARADURA I，
target attainment of isavuconazole against Aspergillus et al. Optimization of fluconazole dosing for the preven‐
fumigatus and Aspergillus flavus in adult patients with tion and treatment of invasive candidiasis based on the
invasive fungal diseases：should therapeutic drug monito- pharmacokinetics of fluconazole in critically ill patients
ring for isavuconazole be considered as mandatory as for [J]. Antimicrob Agents Chemother，2021，65（3）：e01554-
the other mold-active azoles?[J]. Pharmaceutics，2021，13 e01520.
（12）：2099. [20] ZHAO H Z，CHENG J H，ZHOU L H，et al. Induction
[10] FURFARO E，SIGNORI A，DI GRAZIA C，et al. Serial therapy with high-dose fluconazole plus flucytosine for
monitoring of isavuconazole blood levels during pro‐ human immunodeficiency virus-uninfected cryptococcal
longed antifungal therapy[J]. J Antimicrob Chemother， meningitis patients：feasible or not?[J]. Mycoses，2023，66
2019，74（8）：2341-2346. （1）：59-68.
[11] PFALLER M A，CARVALHAES C G，CASTANHEIRA [21] MAERTENS J A，RAHAV G，LEE D G，et al. Pharmaco‐
M. Susceptibility patterns of amphotericin B，itraco- kinetic and exposure response analysis of the double-blind
nazole，posaconazole，voriconazole and caspofungin for randomized study of posaconazole and voriconazole for
isolates causing invasive mould infections from the treatment of invasive aspergillosis[J]. Clin Drug Investig，
SENTRY antifungal surveillance program（2018-2021） 2023，43（9）：681-690.
and application of single-site epidemiological cutoff values [22] BOPPANA M，SENGAR M，JAIN H，et al. A prospective
to evaluate amphotericin B activity[J]. Mycoses，2023，66 study to evaluate the effect of therapeutic drug monitoring-
（10）：854-868. based posaconazole prophylaxis on invasive fungal infec‐
[12] LI F Y，ZHOU M G，JIAO Z，et al. Caspofungin pharma‐ tion rate during acute myeloid leukemia induction therapy
cokinetics and probability of target attainment in ICU [J]. Indian J Hematol Blood Transfus，2024，40（2）：
patients in China[J]. J Glob Antimicrob Resist，2021，25： 204-212.
238-263. [23] WHITMORE T J，YAW M，LAVENDER M，et al. A novel
[13] 何杰，刘冬雪，钟羚君，等. 重症患者体内米卡芬净暴露 highly bio-available itraconazole formulation（SUBA -
®
量有限采样法估算模型的建立[J]. 中国临床药理学与治 Itraconazole） for anti-fungal prophylaxis in lung transplant
疗学，2022，27（11）：1264. recipients[J]. Transpl Infect Dis，2021，23（4）：e13587.
HE J，LIU D X，ZHONG L J，et al. Establishment of a [24] ZHANG J R，LIU Y W，NIE X L，et al. Trough concentra‐
limited sampling strategy to estimate micafungin exposure tion of itraconazole and its relationship with efficacy and
in critically ill patients[J]. Chin J Clin Pharmacol Ther， safety：a systematic review and meta-analysis[J]. Infect
2022，27（11）：1264. Drug Resist，2018，11：1283-1297.
[14] 康烨，张文涛，阎澜. 米卡芬净预防血液系统恶性肿瘤患 [25] KOSMIDIS C，OTU A，MOORE C B，et al. Isavuco-
者侵袭性真菌感染有效性和安全性的 Meta 分析[J]. 中 nazole therapeutic drug monitoring during long-term treat‐
国真菌学杂志，2022，17（1）：12-16. ment for chronic pulmonary aspergillosis[J]. Antimicrob
KANG Y，ZHANG W T，YAN L. Efficacy and safety of Agents Chemother，2020，65（1）：e01511-e01520.
micafungin in preventing invasive fungal infection in pa‐ [26] ABDEL-HAFEZ Y，SIAJ H，JANAJRI M，et al. Tolerabi-
tients with hematological malignancies：a meta-analysis lity and epidemiology of nephrotoxicity associated with
[J]. Chin J Mycol，2022，17（1）：12-16. conventional amphotericin B therapy：a retrospective

中国药房 2024年第35卷第20期 China Pharmacy 2024 Vol. 35 No. 20 · 2569 ·